Biopharma | May 05, 2026
Swiss Biotech Association reports CHF 7.5 billion revenue for Switzerland’s biotech Industry in 2025
The private funding rose 38% amid growing international collaborations and CDMO demand
The private funding rose 38% amid growing international collaborations and CDMO demand
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Discussions focused on digital health, non-communicable diseases, resilient supply chains, medical innovation, and healthcare workforce development
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
Keeps Halo Pharma to drive independent growth
Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows
Subscribe To Our Newsletter & Stay Updated
